Open access
Open access
Powered by Google Translator Translator

Study: pioglitazone versus sulfonylureas in patients with type 2 diabetes

18 Sep, 2017 | 14:04h | UTC

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Commentary: Sulfonylureas, Pioglitazone Similarly Safe for Add-On Therapy in Type 2 Diabetes – Physician’s First Watch (free)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.